Satoru Matsuda

Satoru Matsuda

Auto-generated profile, based on publicly available information

Satoru Matsuda

Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2007 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
MNMasaya Nakanishi
Masaya Nakanishi
TNTetsuhiro Niidome
Tetsuhiro Niidome
SMSatoru Matsuda
Satoru Matsuda
AAAkinori Akaike
Akinori Akaike
TKTakeshi Kihara
Takeshi Kihara
HSHachiro Sugimoto
Hachiro Sugimoto

9 June 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MKMakoto Kiso
Makoto Kiso
STShigekazu Tanaka
Shigekazu Tanaka
RSRie Saba
Rie Saba
SMSatoru Matsuda
Satoru Matsuda
ASAtsushi Shimizu
Atsushi Shimizu
YSYumiko Saga
Yumiko Saga
Hair is maintained through a cyclic process that includes periodic regeneration of hair follicles in a stem cell-dependent manner. Little is known, however, about the cellular and molecular mechanisms that regulate the layered differentiation of the hair follicle. We have established a mutant mouse with a cyclic alopecia phenotype resulting from the targeted disruption of Sox21 , a gene that encodes a HMG-box protein. These mice exhibit progressive hair loss after morphogenesis of the first hair follicle and become completely nude in appearance, but then show hair regrowth. Sox21 is expressed in the cuticle layer and the progenitor cells of the hair shaft in both mouse and human. The lack of this gene results in a loss of the interlocking structures required for anchoring the hair shaft in the hair follicle. Furthermore, the expression of genes encoding the keratins and keratin binding proteins in the hair shaft cuticle are also specifically down-regulated in the Sox21-null mouse. These results indicate that Sox21 is a master regulator of hair shaft cuticle differentiation and shed light on the possible causes of human hair disorders.

5 September 2012 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
SMSatoru Matsuda
Satoru Matsuda
KKKen-Ichiro Kuwako
Ken-Ichiro Kuwako
HOHirotaka James Okano
Hirotaka James Okano
STShuichi Tsutsumi
Shuichi Tsutsumi
HAHiroyuki Aburatani
Hiroyuki Aburatani
Hideyuki OkanoHideyuki Okano
Hideyuki Okano
Despite the importance of the production of new neurons in the adult hippocampus, the transcription network governing this process remains poorly understood. The High Mobility Group (HMG)-box transcription factor, Sox2, and the cell surface activated transcriptional regulator, Notch, play important roles in CNS stem cells. Here, we demonstrate that another member of the SoxB (Sox1/Sox2/Sox3) transcription factor family, Sox21, is also a critical regulator of adult neurogenesis in mouse hippocampus. Loss of Sox21 impaired transition of progenitor cells from type 2a to type 2b, thereby reducing subsequent production of new neurons in the adult dentate gyrus. Analysis of the Sox21 binding sites in neural stem/progenitor cells indicated that the Notch-responsive gene,Hes5, was a target of Sox21. Sox21 repressedHes5gene expression at the transcriptional level. Simultaneous overexpression ofHes5andSox21revealed that Hes5 was a downstream effector of Sox21 at the point where the Notch and Sox pathways intersect to control the number of neurons in the adult hippocampus. Therefore, Sox21 controls hippocampal adult neurogenesis via transcriptional repression of theHes5gene.

22 December 2018 in Neuropsychopharmacology
Verified
Journal Article
Closed access
PDF file
SMSatoru Matsuda
Satoru Matsuda
RBRina Baba
Rina Baba
HOHideyuki Oki
Hideyuki Oki
SMShinji Morimoto
Shinji Morimoto
MTMasashi Toyofuku
Masashi Toyofuku
HKHaruhide Kimura
Haruhide Kimura

12 March 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
RBRina Baba
Rina Baba
SMSatoru Matsuda
Satoru Matsuda
YAYuuichi Arakawa
Yuuichi Arakawa
RYRyuji Yamada
Ryuji Yamada
NSNoriko Suzuki
Noriko Suzuki
HKHaruhide Kimura
Haruhide Kimura
Persistent epigenetic dysregulation may underlie the pathophysiology of neurodevelopmental disorders, such as autism spectrum disorder (ASD). Here, we show that the inhibition of lysine-specific demethylase 1 (LSD1) enzyme activity normalizes aberrant epigenetic control of gene expression in neurodevelopmental disorders. Maternal exposure to valproate or poly I:C caused sustained dysregulation of gene expression in the brain and ASD-like social and cognitive deficits after birth in rodents. Unexpectedly, a specific inhibitor of LSD1 enzyme activity, 5-((1R,2R)-2-((cyclopropylmethyl)amino)cyclopropyl)-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide hydrochloride (TAK-418), almost completely normalized the dysregulated gene expression in the brain and ameliorated some ASD-like behaviors in these models. The genes modulated by TAK-418 were almost completely different across the models and their ages. These results suggest that LSD1 enzyme activity may stabilize the aberrant epigenetic machinery in neurodevelopmental disorders, and the inhibition of LSD1 enzyme activity may be the master key to recover gene expression homeostasis. TAK-418 may benefit patients with neurodevelopmental disorders.

1 January 2018 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
EKEmi Kurimoto
Emi Kurimoto
SMSatoru Matsuda
Satoru Matsuda
YSYuji Shimizu
Yuji Shimizu
YSYuu Sako
Yuu Sako
TMTakao Mandai
Takao Mandai
HKHaruhide Kimura
Haruhide Kimura
Activation of muscarinic M1 receptor (M1R) is a promising approach for improving cognitive impairment in Alzheimer’s disease. However, an M1R-selective positive allosteric modulator (PAM), benzyl quinolone carboxylic acid (BQCA), at 30 mg/kg, induced diarrhea in wild-type mice, but not in M1R knockout mice. Moreover, BQCA (0.1–1000 nM) augmented electric field stimulation (EFS)-induced ileum contraction in an in vitro Magnus assay. Thus, we decided to establish a drug-screening strategy to discover novel M1 PAMs producing potent cognitive improvement with minimized gastrointestinal (GI) dysfunction. We assessed PAM parameters of various M1 PAMs with ≥100-fold selectivity over other muscarinic receptor subtypes by using in vitro binding and functional analysis. Evaluation of these M1 PAMs in the Magnus assay revealed a significant correlation between percentage of ileum contractions at 1 μM and their α-value, a PAM parameter associated with the binding cooperativity between acetylcholine and M1 PAM. M1 PAMs with lower α-value showed lower impact on EFS-induced ileum contraction. Next, we characterized in vivo profiles of two M1 PAMs: compound A (log α = 1.18) and compound B (log α = 3.30). Compound A, at 30 mg/kg, significantly improved scopolamine-induced cognitive deficits without prominent signs of diarrhea at up to 1000 mg/kg in mice. In contrast, compound B, at 10 mg/kg, showed both significant improvement of scopolamine-induced cognitive deficits and severe diarrhea. Thus, fine adjustment of the α-values could be a key to discovering M1 PAMs yielding potent cognitive improvement with a lower risk of GI effects.